CURX — Curanex Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $12.87m
- $7.04m
Annual income statement for Curanex Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS |
| Standards: | USG | USG | USG |
| Status: | Final | Final | Final |
| Revenue | |||
| Total Revenue | 0.026 | 0 | 0 |
| Cost of Revenue | |||
| Gross Profit | 0.004 | 0 | — |
| Selling / General / Administrative Expenses | |||
| Unusual Expense / Income | |||
| Total Operating Expenses | 0.046 | 0.019 | 0.365 |
| Operating Profit | -0.02 | -0.019 | -0.365 |
| Other Net Non Operating Costs | |||
| Net Income Before Taxes | -0.02 | -0.019 | -0.362 |
| Net Income After Taxes | -0.02 | -0.019 | -0.362 |
| Net Income Before Extraordinary Items | |||
| Net Income | -0.02 | -0.019 | -0.362 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||
| Income Available to Common Shareholders Including Extraordinary Items | |||
| Diluted Net Income | -0.02 | -0.019 | -0.362 |
| Diluted Weighted Average Shares | |||
| Basic EPS Including Extraordinary Items | |||
| Diluted EPS Including Extraordinary Items | |||
| Diluted EPS Excluding Extraordinary Items | |||
| Normalised Income Before Taxes | |||
| Normalised Income After Taxes | |||
| Normalised Income Available to Common Shareholders | |||
| Diluted Normalised EPS | -0 | -0.001 | -0.01 |
| Dividends per Share |